Artelo Biosciences (ARTL) news

Artelo Biosciences announces reverse stock split

Artelo Biosciences, Inc. (Nasdaq: ARTL) announced on March 6, 2026, that its Board of Directors approved 3-for-1 reverse stock split , effective March 10, 2026. The move aims to increase the price per share to enhance marketability and liquidity. Following the split, each three shares will be…

Artelo Biosciences secures notice of allowance in Japan for patent claims for the intended commercial formulation of ART27.13

Artelo Biosciences, Inc. (Nasdaq: ARTL) has received a Notice of Allowance from the Japanese Patent Office for patent claims covering the intended commercial formulation of its peripherally selective cannabinoid agonist, ART27.13. The allowed claims protect compositions of ART27.13 dispersed in…

Artelo Biosciences - patent protection for ART27.13 expected through 2041

Artelo Biosciences, Inc. (Nasdaq: ARTL) has received a Notice of Allowance from the European Patent Office (EPO) for its patent application covering the intended commercial formulation of ART27.13, a peripherally selective cannabinoid agonist under evaluation in a Phase 2 clinical trial for the…

Artelo Biosciences - receives USPTO notice of allowance for ART27.13 formulation patent

Artelo Biosciences - initial Dream study results anticipated in Q4 2026

Artelo Biosciences, Inc. (Nasdaq: ARTL) is preparing to advance its clinical pipeline with multiple key milestones expected through 2026 and beyond. The company, which focuses on modulating lipid-signaling pathways to develop treatments for conditions including cancer, pain, and neurological…